ArticleBMC infectious diseases2026
First report of the mcr-1 gene in colistin-resistant Klebsiella pneumoniae in a tertiary care hospital in Tunisia.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColistin resistance mediated by mcr genes poses a critical threat to antimicrobial therapy, particularly in multidrug-resistant Klebsiella pneumoniae. While mcr-1 has been previously identified in clinical Escherichia coli in Tunisia, no human clinical K. pneumoniae isolate carrying this gene has been reported to date.
objectivesThis study aims to assess colistin resistance rates in carbapenem-resistant clinical K. pneumoniae isolates, characterize genetic resistance determinants in resistant strains, and screen for the occurrence of the mcr-1 gene.
methodsThis study was conducted from January to December 2024 at Habib Thameur Hospital, Tunis and investigated colistin resistance among carbapenem-resistant K. pneumoniae isolates. Colistin resistance was assessed via broth microdilution (EUCAST criteria). Resistance genes were detected via multiplex PCR and confirmed via Sanger sequencing. Sequence identity was analysed with BLASTn database.
resultsAmong the 143 carbapenem-resistant K. pneumoniae isolates, 16 [11.2% (95% CI: 6.5-17.5%)] were colistin resistant. All the isolates were multidrug resistant, with a high prevalence of the blaOXA-48-like (14/16) and blaNDM (11/16) carbapenemase genes and the β-lactamases genes blaCTX-M (14/16) and blaSHV (11/16). Additional resistance determinants included the qnrS (14/16), qnrB (15/16), and 16 S rRNA methylase genes (rmtF, rmtC, and armA). One isolate carried the mcr-1 gene, displaying moderate colistin resistance (MIC: 4 mg/L) and harbouring multiple resistance genes.
conclusionThis study reports the first detection of the mobile colistin resistance gene mcr-1 in a clinical K. pneumoniae isolate in Tunisia. While chromosomal mechanisms remain predominant in colistin-resistant K. pneumoniae in the country, this finding underscores the urgent need for enhanced molecular surveillance and antibiotic stewardship to curb the potential risk for future dissemination of mcr-mediated resistance in North Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.